Released Nov 12, 2024, before the open
10-Q filed Nov 12, 2024, 43 days after period end · 0002023658-24-000002
Q3 2024 · 10-Q
Revenue—
Net Income-$17.48M-$17.48M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$1.60-$1.60 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$20,628,000N/M
Operating Cash Flowderived-$17,224,000—
Free Cash Flowderived-$17,232,000—
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Income | -$17.48M | -$22.85M |
| EPS Diluted | -$1.60 | -$38.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR